Bukwang Pharmaceutical Co., Ltd. Overview
Bukwang is a 66-year-old, mid-sized Korean prescription-drug company. In 2022 it moved from founder-family control to the OCI Group, and the business now runs on three engines. The first is a domestic ETC franchise led by diabetic-neuropathy products (Dexid and Thioctacid), liver therapy (Legalon) and iron supplementation (Feroba). The second is a fast-growing CNS franchise built around in-licensed lurasidone (Latuda, launched August 2024), with Exel, Zaledeep, Orfil and the 2026 epilepsy launch Bukwang Brivil alongside it. The third is a Copenhagen-based discovery subsidiary, Contera Pharma, which combines a Phase 2-ready Parkinson's asset (CP-012) with an oligonucleotide/RNA discovery platform validated by an October 2025 research option deal with H. Lundbeck. After two loss years (FY2022–23) and a deep restructuring, Bukwang posted record revenue of KRW 200.7bn in FY2025 and raised KRW 89.3bn of equity. It then bought a court-rehabilitated manufacturer to relieve chronic capacity shortfalls. Management targets KRW 600bn revenue and a top-20 domestic ranking by 2030.
What the company does
Bukwang develops, manufactures, in-licenses and sells finished pharmaceuticals in Korea. Dosage forms include oral solids, injectables, oral solutions, topical solutions and ointments, plus quasi-drugs such as toothpaste [company/aggregator descriptions; IR FY2025]. The company describes its business as making and selling medicines and quasi-drugs. Its stated management philosophy is to contribute to a stable supply of medicines and serve society through high-quality production, with an ambition to become a global pharma-bio company [IR FY2025 Fact Book, "Vision"]. Bukwang calls its R&D model "Global Open Innovation". In practice that means subsidiaries, joint ventures, research collaborations, equity investments and fund commitments, focused on CNS and oncology [IR FY2025].
Business model and revenue model
Product sales dominate: Revenue is almost entirely product sales to wholesalers, hospitals and pharmacies in Korea. Manufactured products ("제품") sit alongside traded and co-promoted goods ("상품"). An aggregator breakdown of Q2 FY2026 revenue shows other manufactured products 31%, merchandise (traded goods) 22%, Dexid 9%, Feroba 7% and Latuda 7% [butler.works, sourced from DART, Q2-2026].
Licensing and collaboration revenue is emerging: Contera Pharma booked about KRW 10.7bn in FY2025, believed to be largely the Lundbeck upfront payment [Dealsite, Jun-2026]. Further Lundbeck research funding was recognised in Q2 FY2026 [Dailypharm, Jul-2026]. Future milestones and royalties are possible.
Contract manufacturing (CMO) is nascent: Bukwang Unipharm (formerly Korea Union Pharm) began contract-making Bukwang products in June 2026. Management has said a synthetic-drug CDMO business is a medium-term option once capacity stabilises [Dealsite, Jun-2026; Medigatenews, Jul-2026].
Co-promotion: Since 1 April 2026 Bukwang co-promotes Servier Korea's Acertil and Vastinan brands (7 SKUs), covering hospitals and clinics under 300 beds [Dailypharm, Mar-2026].
Exports are immaterial: An aggregator shows FY2025 export revenue of KRW 0.7 x 100M [valueline.co.kr]. Overseas revenue in practice comes from Contera's collaboration income.
No subscription model: ### Value-chain position
Bukwang is an integrated, domestic-market finished-dose company. It covers formulation R&D and in-house incrementally modified drugs (IMDs, "개량신약"), in-licensing of foreign originals, manufacturing at Ansan (and Wonju from 2026), and specialty sales forces. It does not produce APIs at scale; raw-material supply problems hit certain antivirals in 2023 [IR FY2023]. Since 2023 the Ansan plant has run above 100% utilisation (115% in Q1-2026; 122% average in late 2025). About 20% of FY2025 revenue relied on outsourced production [Dailypharm, May-2026; Dealsite, Jun-2026].
Customers and end-markets
Customers: pharmaceutical wholesalers, tertiary and general hospitals, psychiatric hospitals, clinics, pharmacies (OTC and toothpaste) and, through Contera, global pharma partners (Lundbeck).
Therapeutic end-markets: diabetic neuropathy and complications; CNS (schizophrenia, bipolar depression, depression, insomnia, epilepsy, dementia); hepatology (Legalon, Regadex, legacy hepatitis-B antivirals); haematology/nutrition (Feroba); gastroenterology (Selbex, pancreatin combination); cardiovascular and metabolic (Servier co-promotion, Eroset, Budiang); consumer health (Tacenol, Sirinmed toothpaste).
Independent characterisation
Bukwang is a turnaround and re-rating story inside a chemical conglomerate's pharma ambitions. The ETC base is steady and low-growth; the 2025 jump came mainly from recovered supply of the thioctic-acid franchise and the Latuda launch. Underneath sit a capacity bottleneck now being fixed through acquisition, and an option-like R&D subsidiary. Contera has consumed about KRW 120bn of Bukwang capital over 12 years [Dealsite, Jun-2026] and only in 2025 produced external validation. Group-level questions also bear on the equity story: OCI Holdings' need to reach 30% ownership by September 2027 and its own solar-sector exposure.
Strategy
Stated strategy (paraphrased from FY2025 IR, AGM 2025/2026 and investor calls)
-
Top-20 domestic pharma by 2030. Target revenue of KRW 600bn and double-digit operating profit [Dealsite Jun-2026, citing the Mar-2026 AGM]. Levers are IMDs, first generics and global new-drug pipelines.
-
Become a CNS specialist. Expand Latuda (first-line bipolar positioning, higher-dose schizophrenia use, paediatric psychiatry, MDD label extension) and add launches (Brivil, Circadeep, Ariplus).
-
Fix supply. Add capacity (Ansan automation, the Union/Unipharm acquisition, MES) to end recurring stock-outs and cut outsourcing costs. Use surplus capacity for CMO/CDMO later.
-
R&D "selection and concentration". Prioritise CP-012 and the RNA platform. Wind down Protekt and Dyna. Spin the RNA business into a new Danish company to attract outside VC and make an M&A exit easier [Dealsite Nov-2025; Edaily].
-
Shareholder returns. Interim and quarterly dividends. Met Korea's "high-dividend company" test for FY2025, making separate dividend taxation available to shareholders [Medigatenews Mar-2026]. Earlier statements mentioned treasury-share buyback and cancellation [Medifonews Mar-2025].
Initiatives in the last 24 months
| Date | Initiative | Detail / targets |
|---|---|---|
| Mar–Jul 2025 | KRW 89.3bn rights offering | Use of proceeds: manufacturing expansion KRW 34bn (38%); new equipment KRW 8.6bn (10%; solid-dose line KRW 7.1bn, MES KRW 1.5bn); acquisition of a manufacturer KRW 30bn (34%); R&D working capital KRW 16.7bn (18%). Original KRW 100bn plan: plant KRW 49.5bn, acquisition KRW 35bn, R&D KRW 30bn [Kukinews Apr-2025; IR Q1-26] |
| 2,025 | CNS sales force expansion | Larger specialist team for Latuda coverage |
| Oct 2025 | Lundbeck RNA collaboration (Contera) | Two Lundbeck-chosen targets; upfront, full research funding per target, milestones, tiered royalties |
| Nov 2025 | RNA subsidiary plan | CNS-focused RNA company in Denmark; talks with overseas VCs; Danish tax pre-approval filed in Q1-26; completion targeted Q4 2026 |
| 2025–2026 | Shareholder returns | KRW 50 interim (Nov 2025) plus KRW 75 final; total KRW 12.3bn, about 98% payout |
| Dec 2025 – Oct 2026 | Union Pharm acquisition and integration | Board replaced (Jun 2026); rehabilitation ended (31 Aug 2026); renamed Bukwang Unipharm (8 Oct 2026); production transfers (pancreatin combination, Hard Chewable) |
| Q1 2026 | KRW 50bn fund commitment | Bukwang to anchor a KRW 50bn bio fund run by QUAD as strategic investor |
| Mar 2026 | Servier co-promotion | Cardiovascular adjacency |
| May 2026 | AI/organoid MOU | With Dream CIS (CRO; organoid NAMs) and AWS (cloud/AI): joint pilot on organoid toxicity plus AI analytics, AI trial design, regulatory science |
| 2,026 | Latuda MDD Phase 3 | IND approved; about two-year study |
| 2,026 | CP-012 Phase 2 | Global IND filed; about two-year programme; topline Q1 2028 |
ESG commitments. ISO 14001 and ISO 45001 certified. Mid- to long-term carbon-neutrality target disclosed (details NPD). Human-rights impact assessment. Fair-trade compliance programme [IR FY2025].
Guidance
FY2026: operating profit to be volatile because of CP-012 Phase 2 spend and the Lundbeck base effect, but the company aims to stay profitable [CEO, Q1-26 call]. Gradual margin recovery from H2 2026 [Q2-26 call].
Medium term: KRW 600bn revenue by 2030.
- No numerical FY2026 revenue guidance was found (NPD).
Products & Services
Prices are set by Korea's National Health Insurance reimbursement for ETC products and are not disclosed product by product in the sources reviewed (NPD). The catalog lists named products identified in company disclosures and trade press. It is not exhaustive: Bukwang's full ETC list runs to dozens of SKUs.
Diabetic neuropathy / metabolic franchise (core cash generator)
| Product | Molecule / type | Indication | Origin / year | Notes |
|---|---|---|---|---|
| Dexid (덱시드) | Thioctic acid tromethamine (R-enantiomer IMD) | Diabetic polyneuropathy | In-house IMD (2010s) | Largest single product: KRW 4.6bn in Q1-26; about 9% of revenue [Dealsite Jun-2026; butler.works]; export deals with five Southeast Asian countries [IR 2Q18] |
| Thioctacid / Thioctacid HR | Thioctic acid | Diabetic polyneuropathy | Launched 1998 / HR 2003 | KRW 2.4bn in Q1-26. Dexid + Thioctacid revenue +181% (FY2024) and +43% (FY2025), driven by recovered supply [Bizwatch; IR FY2025] |
| Budiang (부디앙) | Empagliflozin (generic) | Type 2 diabetes | Oct 2025 | New chronic-disease launch [Sidae Oct-2025] |
| Eroset (에로젯정 1/10mg) | Pitavastatin + ezetimibe | Hypercholesterolaemia / mixed dyslipidaemia | Aug 2026 | Low-dose statin combination [Dailian Aug-2026] |
CNS franchise (growth engine; "CNS Business Division" set up 2024)
| Product | Molecule | Indication | Origin / year | Notes |
|---|---|---|---|---|
| Latuda (라투다정) | Lurasidone HCl | Schizophrenia; bipolar I depression | Sumitomo Pharma licence (Apr 2017); MFDS approval Nov 2023; launched Aug 2024 | FY2025 sales KRW 11.0bn; monthly sales above KRW 1bn from May 2025; 44/47 tertiary hospitals coded; prescribed at 139 general hospitals, 120 psychiatric hospitals and 1,034 clinics; ranked 6th in the schizophrenia/bipolar market in Q4-25 [IR FY2025]. Q1-26 outpatient prescriptions +153% YoY [IR Q1-26]. MDD adjunct Phase 3 IND approved (disclosed 2 Jun 2026) |
| Exel (익셀) | Antidepressant (company CNS portfolio) | Depression | In-licensed (NPD) | FY2025 +11.3% [IR FY2025] |
| Zaledeep (잘레딥) | Hypnotic | Insomnia | Portfolio product | FY2025 +33.6%; Q1-26 +30% |
| Circadeep / Circadeep SR (서카레딥) | Melatonin | Insomnia | Q4 2025 / Q1 2026 | New launches [Sidae Oct-2025; IR Q1-26] |
| Lonasen (로나센) | Antipsychotic | Schizophrenia | Portfolio product | Listed among core CNS products [IR FY2025] |
| Orfil family (오르필 ER, syrup, injection) | Valproate | Epilepsy (first-line) | Portfolio product | FY2025 +5.9%; Q1-26 +14% |
| Bukwang Brivil (부광브리필정) | Brivaracetam (3rd-generation AED) | Epilepsy (focal seizures) | In-house institute; launch symposium 14–15 Mar 2026 | Reimbursement expected around June 2026 [Medifonews Mar-2026] |
| Ariplus (아리플러스) | Dementia combination | Alzheimer's dementia | Q2 2025 | Neurology launch [Dealsite Apr-2025] |
Hepatology / gastroenterology / haematology
| Product | Molecule | Indication | Notes |
|---|---|---|---|
| Legalon (레가론) | Silymarin (milk thistle) | Liver cirrhosis / hepatocyte support | KRW 3.5bn in Q1-26; reimbursement retained (2026 priority) [IR FY2025; Dealsite] |
| Regadex (레가덱스) | Ursodeoxycholic acid + biphenyl dimethyl dicarboxylate | Liver function | H2 2025 launch |
| Feroba-U SR (훼로바) | Oral iron | Iron deficiency | KRW 3.9bn in Q1-26; about 7% of revenue |
| Selbex (셀벡스) | Teprenone | Gastritis | Q1-26 prescriptions +104% |
| Dilastin (딜라스틴) | NPD | NPD | Q1-26 prescriptions +16% |
| Complex Pazyme (복합파자임이중정) | Pancreatin combination | Digestive | First product made at Union/Unipharm (shipped Jun 2026) |
| Levovir (레보비르) | Clevudine | Chronic hepatitis B | 2006 Korean new drug; legacy |
| Bukwang Adefovir; Taprid; Entecavir | NA antivirals | Hepatitis B | Legacy antiviral line; API supply issues in 2023 |
Cardiovascular (co-promotion since 1 Apr 2026)
| Product | Molecule | Indication | Arrangement |
|---|---|---|---|
| Acertil 4/8mg | Perindopril tert-butylamine | Hypertension | Servier Korea co-promotion; Bukwang alone covers clinics under 100 beds and co-covers 100–299 beds |
| Acertil Arginine 5/10mg | Perindopril arginine | Hypertension | Same |
| Acertil Plus Arginine | Perindopril arginine + indapamide | Hypertension | Same |
| Vastinan / Vastinan MR | Trimetazidine HCl | Stable angina (add-on) | Same |
| Addtamin; Lodivan | NPD | Chronic disease | New launches, Q2 2026 [IR Q1-26] |
Consumer health / OTC / quasi-drugs
| Product | Category | Notes |
|---|---|---|
| Tacenol (타세놀) | Acetaminophen analgesic/antipyretic | COVID-era demand driver [Dealsite 2022] |
| Sirinmed (시린메드) | Sensitive-teeth toothpaste | Trademark since 2005; toothpaste manufacturing partly outsourced [IPqwery; Dealsite Apr-2026] |
| Hard Cal-C Plus; Hard Chewable / Chewable Easy | Vitamin/mineral (ViC) OTCs | Production moving to Unipharm from Sep 2026 |
| Ozanex cream (오자넥스) | Antibiotic ointment | Launched 2022 |
Development portfolio (see §13 for detail)
| Asset | Owner | Indication | Stage (Oct-2026) |
|---|---|---|---|
| Lurasidone (new indication) | Bukwang | MDD adjunct | Korean Phase 3 IND approved; topline targeted Q1 2028; final CSR H1 2028 |
| CP-012 | Contera | Parkinson's morning akinesia ("early-morning OFF") | Global Phase 2 IND filed (80 patients, 25 sites, US + Poland/Italy/Spain) |
| CP-102 | Contera | Canavan disease (NAT8L-targeting ASO) | Preclinical; 28-week NHP data Apr 2026 |
| CP-10X | Contera | Chronic kidney disease | Exploratory |
| Lundbeck targets (2) | Contera / Lundbeck option | Undisclosed neurological diseases | Discovery |
| BUK-001 | Bukwang | Parkinson's disease | Candidate selection, H1 2026 |
| AhR antagonist | JaguAhR | Solid tumours | Under review |
| Controlled-release IMD (CNS) | Bukwang | CNS (undisclosed) | Pilot clinical study |
| Long-acting injectables | Bukwang (+ partners) | NPD | Research |
Financial Narrative
Income statement (consolidated, KRW 100M unless stated)
Margins (%, derived):
Revenue CAGR FY2021–FY2025: 2.4% (derived). From the FY2023 trough to FY2025 the CAGR is 26.3%.
Quarterly trajectory (consolidated, KRW 100M):
[IR Q1-26 quarterly chart; Dealsite/Medigatenews.] 2Q25 operating profit was KRW 21 x 100M in the July 2025 release. H1-2026 revenue was KRW 104.8bn (+15.9%), the first half-year above KRW 100bn, while operating profit was KRW 2.5bn (−49.9%).
Commentary: trends, inflections and drivers.
-
FY2022 inflection to losses. The parent stayed profitable (separate operating profit of KRW 12.3bn), but Contera's R&D for the JM-010 Phase 2 programmes in the US, EU and Korea more than doubled. Derivative valuation losses on Contera's financial-investor contracts and mark-downs on listed investments such as Acer Therapeutics pushed net loss above operating loss [IB Tomato Mar-2023; Dealsite Jul-2022].
-
FY2023 trough. This was largely self-inflicted and partly cosmetic. Under OCI's active involvement from Q3 2023, the company cut credit sales, shortened receivable terms, cut channel inventory, tightened distributor margins, pruned low-margin products and accepted returns while consolidating wholesalers. API supply problems in antivirals and the fading of COVID-related demand added to the decline [IR FY2023]. Receivables fell from KRW 78.0bn (3Q22) to KRW 58.3bn (3Q23), then to about KRW 23.4bn (3Q24); receivable days improved from 101 to 56 [Dailypharm Nov-2024].
-
FY2024 recovery. Supply of the thioctic-acid franchise recovered (+181%), CNS strategic products grew 42%, Latuda launched in August, and cost cuts took effect. The return to a small operating profit was the first since FY2021 [Bizwatch Feb-2025].
-
FY2025 record. Revenue was KRW 200.7bn and operating profit KRW 14.1bn (+775%). Drivers were Dexid/Thioctacid (+43%), CNS strategic products (+91% against a 7.4% market), Latuda (KRW 11.0bn), Bukwang Medica and the Lundbeck upfront. Parent operating profit actually fell 5.5% to KRW 16.1bn on symposium and marketing spend; the consolidated improvement came from subsidiaries turning profitable [IR FY2025].
-
FY2026 year to date: margin compression. Higher outsourced production (to prevent stock-outs), FX-driven input costs, launch marketing, the absence of a Lundbeck upfront and early CP-012 Phase 2 spend cut H1 operating margin to about 2.4% [IR Q1-26; Medigatenews Jul-2026]. Management guides to gradual normalisation in H2.
Balance sheet (consolidated, KRW 100M)
Sources and notes. IR FY2023 and FY2025 Fact Books. The DART-based aggregator valueline shows FY2025 cash and equivalents of 962 plus short-term financial instruments of 1,200, which sum to the IR's 2,162. FY2021 balance sheet is NPD in sources reviewed. The KRW 80bn of borrowings arose in FY2023 and was described as long-term; its FY2024–25 short/long split is NPD. Goodwill is not separately disclosed. Working capital cannot be computed because current liabilities are not split out in IR materials (NPD).
Commentary. The KRW 89.3bn rights offering (July 2025) lifted equity by about KRW 97.5bn and left the group in net cash of about KRW 136bn at FY2025 year end. Roughly KRW 30bn of that went into Union in May 2026, and planned capex at Ansan (KRW 34bn facility expansion plus KRW 8.6bn equipment) is still mostly unspent. Q1-26 aggregator data show cash of 1,144 plus short-term instruments of 970 [valueline].
Cash flow (consolidated, KRW 100M)
Commentary. OCF was negative in FY2023 because inventory rose during the trade restructuring. FY2024 OCF of KRW 34.4bn reflects the collection of about KRW 52bn of receivables. FY2025 OCF moderated as inventories grew with sales and outsourced production.
Ratios (derived from the tables above)
Notes.
-
FY2022 averages need FY2021 balances (NPD).
-
ROIC is NPD: tax and invested-capital detail is not available.
-
Current ratio is NPD: current liabilities are not disclosed in IR.
-
Net debt/EBITDA is not meaningful because the group is in net cash.
-
Interest coverage is NPD: interest expense is not disclosed. With KRW 80bn of borrowings and FY2025 EBIT of KRW 14.1bn, coverage is probably comfortable, but it cannot be verified.
-
Payables include "other payables", which distorts the FY2023 figure.
-
Aggregators show TTM ROE of 4.1–4.2% (valueline/StockHub, mid-2026), consistent with the table.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Bukwang stake | Function | Status |
|---|---|---|---|---|
Bukwang Pharmaceutical (parent) | Korea | — | ETC, OTC, CNS, manufacturing (Ansan) | Operating |
Bukwang Medica Co., Ltd. | Korea | Consolidated (stake NPD) | Consumer health / OTC distribution | Operating; revenue up about 40% YoY in Q2-26 [Dailypharm Jul-2026]; sold Ansan Banwol site and KGMP facility in 2025 [KIRS] |
Contera Pharma A/S | Denmark | 99.9% (Q4-25) → 100% (Q1-26) | CNS small-molecule (CP-012) and RNA/oligo discovery | Operating; RNA spin-off pending |
JaguAhR Therapeutics | Singapore | 75.02% | AhR antagonist (immuno-oncology) | Partner ASLAN liquidated (17 Jul 2024); follow-on direction under review |
Protekt Therapeutics | Israel | 96.53% | Neurodegeneration (PKR inhibitor) | Liquidation begun Q1-2026 |
Dyna Therapeutics | Korea | — | SOL-804 (prostate cancer) | Liquidated (date NPD) |
Bukwang Unipharm (ex-Korea Union Pharm) | Korea (Wonju) | 75.14% | Solids, liquid injections, cephalosporin powder injections | Consolidated from about Q2/Q3-2026; renamed 8 Oct 2026 |
Revenue by Segment (KRW) and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Consolidated revenue (KRW 100M) | 1,825 | 1,909 | 1,259 | 1,601 | 2,007 |
Parent (separate) revenue (KRW 100M) | 1,816 | 1,903 | 1,252 | 1,576 | 1,673 |
Subsidiaries net of eliminations, revenue (KRW 100M, derived) | 9 | 6 | 7 | 25 | 334 |
Parent operating profit (KRW 100M) | 132 | 123 | -166 | 170 | 161 |
Consolidated operating profit (KRW 100M) | 56 | -2 | -364 | 16 | 141 |
Gap: subsidiaries' net operating drag (KRW 100M, derived) | -76 | -125 | -198 | -154 | -20 |
Parent operating margin (%) | 7.3 | 6.5 | -13.3 | 10.8 | 9.6 |
Parent revenue contribution to group (%) | 99.5 | 99.7 | 99.4 | 98.4 | 83.4 |
Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Consolidated revenue growth (%) | 4.6 | -34.0 | 27.2 | 25.4 |
Parent revenue growth (%) | 4.8 | -34.2 | 25.9 | 6.1 |
Income Statement (KRW) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 1,825 | 1,909 | 1,259 | 1,601 | 2,007 |
Revenue growth YoY (%) | 7.5 | 4.6 | -34.0 | 27.2 | 25.4 |
Cost-of-sales ratio (%) | 58.5 | 58.4 | 62.6 | 53.6 | 54.2 |
Gross profit (KRW 100M, derived) | 757 | 794 | 471 | 743 | 919 |
R&D cost (KRW 100M) | 225 | 243 | 342 | 284 | 262 |
R&D / revenue (%) | 12.3 | 12.7 | 27.2 | 17.7 | 13.0 |
Operating profit (KRW 100M) | 56 | -2 | -364 | 16 | 141 |
EBITDA (KRW 100M) | 103 | 40 | -324 | — | — |
Net income, consolidated (KRW 100M) | -28 | -42 | -344 | -35 | 126 |
Net income attributable to owners (KRW 100M) | -9 | -25 | -313 | -26 | 126 |
Basic EPS (KRW) | -13 | -36 | -458 | -39 | 152 |
Cash DPS (KRW) | 100 | 0 | 0 | 0 | 125 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 41.5 | 41.6 | 37.4 | 46.4 | 45.8 |
Operating margin (%) | 3.1 | -0.1 | -28.9 | 1.0 | 7.0 |
EBITDA margin (%) | 5.6 | 2.1 | -25.7 | — | — |
Net margin, consolidated (%) | -1.5 | -2.2 | -27.3 | -2.2 | 6.3 |
Financial Analysis
| Metric | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
Revenue (KRW 100M) | 478 | 426 | 478 | 625 | 478 | 570 |
Operating profit (KRW 100M) | 30 | 20 | 10 | 82 | 11 | 14 |
Net income (KRW 100M) | -1 | 64 | — | — | 12 | 14 |
Balance Sheet (KRW) and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW 100M) | 4,009 | 4,293 | 3,731 | 4,774 |
Current assets (KRW 100M) | 2,187 | 2,517 | 2,037 | 3,061 |
Cash, equivalents and short-term deposits (KRW 100M) | 855 | 1,529 | 1,301 | 2,162 |
Trade receivables (KRW 100M) | 880 | 357 | 236 | 278 |
Inventories (KRW 100M) | 386 | 569 | 417 | 522 |
PP&E (KRW 100M) | 1,219 | 1,211 | — | — |
Intangible assets (KRW 100M) | 70 | 88 | — | — |
PP&E + intangibles (KRW 100M) | 1,289 | 1,299 | 1,467 | 1,488 |
Investments in funds/shares (KRW 100M) | 198 | 197 | 167 | 162 |
Borrowings, total (KRW 100M) | 0 | 800 | 800 | 800 |
Trade and other payables (KRW 100M) | 165 | 24 | 176 | 232 |
Total liabilities (KRW 100M) | 1,291 | 1,978 | 1,290 | 1,358 |
Total equity (KRW 100M) | 2,718 | 2,315 | 2,441 | 3,416 |
Liabilities / equity (%) | 47 | 86 | 53 | 40 |
Net debt, negative = net cash (KRW 100M, derived) | -855 | -729 | -501 | -1,362 |
Cash Flow (KRW)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW 100M) | 265 | 165 | -105 | 344 | 185 |
Dividends paid in year (KRW 100M) | — | — | 0 | 0 | 49 |
Share cancellation, book value (KRW 100M) | 0 | 0 | 0 | 500 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average equity (%) | — | -13.7 | -1.5 | 4.3 |
ROA on average assets (%) | — | -8.3 | -0.9 | 3.0 |
Debt / equity (%) | 0.0 | 34.6 | 32.8 | 23.4 |
Asset turnover on average assets (x) | — | 0.30 | 0.40 | 0.47 |
Receivable days (year-end) | 168 | 103 | 54 | 51 |
Inventory days on COGS (year-end) | 126 | 264 | 177 | 175 |
Payable days on COGS (year-end) | 54 | 11 | 75 | 78 |
Cash conversion cycle (days, approximate) | 240 | 356 | 156 | 148 |
Region (KRW 100M) Overview
| Region (KRW 100M) | FY2025 |
|---|---|
Korea, all product and other revenue (KRW 100M, derived) | 1,900 |
Denmark, Contera collaboration revenue (KRW 100M) | 107 |
Product exports from Korea (KRW 100M, aggregator) | 1 |
Dosage Form Details
| Dosage form (KRW 100M) | FY2025 |
|---|---|
Film-coated tablets | 838 |
Plain tablets | 246 |
Capsules | 239 |
Sugar-coated tablets | 13 |
Injectables | 91 |
Valuation Multiples (KRW)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 7,998 | 5,576 | 4,196 | 3,785 |
Year-end market cap (KRW 100M) | 6,218 | 4,335 | 3,142 | 3,734 |
Capital Markets
| Metric | Bukwang | Whanin | Samjin | Boryung |
|---|---|---|---|---|
P/E TTM (x) | 46.7 | 9.1 | 10.6 | 6.4 |
P/B (x) | 1.23 | 0.44 | 0.82 | 0.86 |
Dividend yield (%) | 3.0 | 3.0 | 4.3 | 1.8 |
EV/Sales FY2025 (x, derived) | 1.36 | NPD | NPD | NPD |
EV/EBITDA (x) | NPD | NPD | NPD | NPD |
Analyst Conclusions
Management guidance
-
FY2026: profitable but volatile operating income; H2 margin normalisation; Unipharm synergies; CP-012 Phase 2 start; RNA NewCo by Q4 2026.
-
2030: KRW 600bn revenue (about 3x FY2025) and a top-20 ranking.
-
No numerical FY2026 revenue or earnings guidance; no sell-side consensus.
Bull case
-
CNS compounding. Latuda grew 153% in Q1-26 prescriptions and holds 44/47 tertiary hospital codings. Add a possible MDD label in 2028 and new launches (Brivil, Circadeep), and CNS could become a KRW 50bn-plus franchise, re-rating Bukwang towards specialist peers.
-
Capacity unlock. Unipharm adds about 30% solid capacity and about 2x injectables. Insourcing about 20% of revenue now made by third parties should recover gross margin lost to outsourcing (consolidated COGS ratio rose from 56.3% to 60.2% YoY in Q1-26).
-
R&D optionality at low cost. A positive CP-012 Phase 2 (topline Q1 2028) or a funded RNA NewCo with further Lundbeck milestones could produce non-dilutive value well above Contera's book value. OCI's 30% requirement adds a technical bid.
Bear case
-
Margin structure. Even at record revenue, FY2025 operating margin was only 7%, and H1-26 fell to about 2.4%. The 2030 double-digit margin target looks distant, and P/E of about 47x already discounts a recovery.
-
Execution risk on a distressed asset. Unipharm ran at 29% utilisation, was capital-impaired and delisted. Normalisation costs and possible extra funding needs could absorb cash, as flagged when the deal was announced.
-
R&D track record. JM-010, Protekt, Dyna and SOL-804 all failed or were abandoned after heavy spending. CP-012 Phase 2 is small and the Lundbeck economics are undisclosed. The March 2026 spike (+154% year to date) and subsequent −55% show how sentiment-driven the RNA narrative is.
Catalysts and monitorables (next 12 months)
-
Q3-26 results (late Oct 2026) and Q4/FY2026 results (Feb 2027): margin recovery against outsourcing costs.
-
Approval and first patient dosed in the CP-012 Phase 2 (US/EU).
-
Formation and outside funding of the RNA NewCo (Q4 2026); any Lundbeck milestone or target-option news; a CP-102 partnering deal.
-
Unipharm: transfer of production, first external CMO contracts, path to break-even.
-
Latuda MDD Phase 3 enrolment; quarterly Latuda prescription data (UBIST).
-
OCI Holdings' actions on the 30% requirement (deadline Sep 2027).
-
Dividend declarations (interim and quarterly) and maintenance of high-dividend status.
-
Korean drug-price reform implementation.
Analyst verdict
Bukwang Pharmaceutical is no longer the founder-run, R&D-dispersed company that drifted into losses in 2022–23. Under OCI it has become a leaner, better-capitalised domestic specialist. The core business is now clean: receivable days have roughly halved, channel inventory has been reset and the group holds net cash. Growth is real. Revenue rose from KRW 125.9bn in FY2023 to a record KRW 200.7bn in FY2025, and H1-2026 continued at +16%. That growth comes from a credible CNS franchise and a recovered thioctic-acid line rather than one-off items, although FY2025 profit did benefit from the Lundbeck upfront.
Profitability is where the case is unresolved. The company has spent three years running a plant beyond nameplate capacity and buying third-party production to avoid stock-outs. That cost explains most of the H1-2026 margin compression and is exactly what the Unipharm acquisition is meant to fix. If insourcing works through 2027, operating margins should move back above high single digits without heroic assumptions. If integration stalls, Bukwang remains a low-margin distributor of other companies' molecules trading at a specialist multiple.
The equity therefore splits into two parts. One is a domestic franchise that at peer multiples (P/E around 10x, P/B under 1x) would justify a materially lower valuation than today's. The other is an option on CP-012 and the Contera RNA platform, which the market prices on news flow, as the round trip from roughly KRW 3,800 to 9,890 and back to about KRW 4,100 in 2026 shows. The sponsor overlay (OCI's 30% deadline) offers technical support but does not change fundamentals. Overall, Bukwang is an improving but not yet proven operating story with asymmetric but binary R&D upside. Evidence of margin recovery from Unipharm and a dosed CP-012 Phase 2 are the two signals that would justify the current premium.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure (approx.) | Background |
|---|---|---|---|
Ahn Mi-jung (안미정) | Chairman; inside director | Board since 26 Mar 2025 | Representative patent attorney at Jipyong patent firm; adjunct professor of materials science, Yonsei University; OCI Holdings board chair from Mar 2024 (first woman outside-director chair in OCI Group); former outside director of Genexine and Medipost [Medigatenews Mar-2025] |
Lee Je-young (이제영) | CEO (representative director) | CEO since 2024 per IR (sources conflict: Dealsite says Mar 2023, TheGuru says Mar 2024; IR materials list Lee Woo-hyun as CEO at Dec 2023 and Lee Je-young by Apr 2024) | Former public prosecutor (17 years); joined OCI 2019; executive VP, OCI Holdings strategy office, led OCI's holding-company conversion [TheGuru] |
Kim Sung-soo (김성수) | Executive VP, Head of Business | Since 2024 (earlier Head of Management Strategy) | Appointed inside director of Bukwang Unipharm, Jun 2026 |
Sung Kwang-hyun (성광현) | Executive VP, Union Acquisition TF; representative director of Bukwang Unipharm | 2,026 | Ex-OCI Holdings |
Kim Min-gyu (김민규) | Head of Management Strategy; filing officer | 2025–2026 | Signatory on the H1-2025 semi-annual report |
Kim Ji-heon (김지헌) | Head of R&D | Joined 2023 | Advocates disciplined portfolio pruning |
Lee Sang-gil (이상길) | Outside director; audit committee | Since Mar 2025 | Professor at Yonsei Severance; former head of the Yonsei Cancer Hospital gastric cancer centre |
Jung Gil-young (정길영) | Outside director | In office at Mar 2026 AGM | NPD |
Jeon Hyung-soo (전형수) | Outside director | In office at Mar 2026 AGM | NPD |
Thomas Sager | CEO, Contera Pharma | Since about 2021 | Former Lundbeck VP; more than 25 years in neurology |
Søren Vestergaard Rasmussen | CSO, Contera Pharma | — | Presented CP-102 primate data, Apr 2026 |
Anne Birk Østerskov | CMO, Contera Pharma | — | Led CP-012 Phase 1b |
Shareholding Trend
| Shareholder (% of shares) | Dec-2023 | Dec-2025 |
|---|---|---|
OCI Holdings Co., Ltd. (%) | 10.90 | 17.11 |
Kim Dong-yeon, co-founder (%) | 9.93 | 7.15 |
Chung Chang-soo, co-founder / vice-chairman (%) | 8.51 | 6.13 |
National Pension Service (%) | 2.02 | 0.70 |
Foreign investors, aggregate (%) | 4.33 | 5.89 |
Treasury shares (%) | 3.67 | 0.00 |
Others / retail (%) | 60.64 | 63.02 |
Competitive Landscape
Peer Comparison FY2025
| Company | Revenue FY2025 (KRW 100M) | Revenue growth (%) | Operating profit (KRW 100M) | Operating margin (%) | R&D / sales (%) | Market cap (KRW 100M, 2026) |
|---|---|---|---|---|---|---|
Bukwang | 2,007 | 25.4 | 142 | 7.1 | 13.0 | 4,100 |
Whanin Pharm | 2,552 | -1.7 | 130 | 5.1 | NPD | 1,867 |
Myungin Pharm | 2,873 | NPD | 925 | 32.2 | NPD | NPD |
Samjin Pharm | 3,091 | 0.3 | 268 | 8.7 | about 12 (Q1-26 12.2) | 2,455 |
Myungmoon Pharm | 1,952 | 4.7 | 68 | 3.5 | NPD | 413 |
Boryung | 10,174 | 0.0 | 651 | 6.4 | NPD | 7,721 |
Recent Developments
Leadership changes in the period: Ahn Mi-jung became chairman (Mar 2025); the Union board was reconstituted (Jun–Jul 2026).



